EGFR and hepatocellular carcinoma: Thus, HOXB5 is a prognostic biomarker in human HCC, and targeting miR-200a-3p or the miR-181-5p/HOXB5/EGFR signaling pathway may provide evidence for the treatment strategies for HCC.